{"groups":[{"description":"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -7, receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.\n\nTRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day 0.\n\nPOST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also receive methotrexate IV on days 1, 3, 6, and 11.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMethotrexate: Given IV\n\nPeripheral Blood Stem Cell Transplantation: Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant\n\nT Cell-Depleted Hematopoietic Stem Cell Transplantation: Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant\n\nTacrolimus: Given IV or PO\n\nThiotepa: Given IV\n\nTotal-Body Irradiation: Undergo TBI","id":"FG000","title":"Treatment (CD45RA+ T Cell Depleted PBSCT)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"Day 28 Post Transplant"},{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"Day 100 Post Transplant"},{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"1 Year Post Transplant"},{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of the 20 patients enrolled, all 20 met inclusion criteria and went forward to be treated on the study.","recruitmentDetails":"Participants were recruited based on referral for Hematopoietic Cell transplant at Fred Hutchinson Cancer Center between March 2014 and January 2017. The first participant was enrolled on April 10, 2014 and the last participant was enrolled on January 27, 2017."}